Stingray acquires Oncogard
STINGRAY HEALTHCARE CONTINUES ITS DEVELOPMENT IN FRANCE THROUGH A PARTNERSHIP WITH ONCOGARD IN NÎMES
21.11.2022 – Stingray Healthcare (“Stingray”, formerly known as MedEuropa Group), an alliance of medical professionals, healthcare managers and entrepreneurs committed to the support and development of cancer care practices, has finalised a partnership with Oncogard’s shareholding doctors in Nîmes to support the long-term provision of cancer care in the region.
As the only private radiotherapy centre in the Gard region of France, Oncogard provides high-quality treatments to over 1,100 patients per year in Nîmes and the surrounding area. In addition, Oncogard offers oncology consultations and chemotherapy treatments at its main site in Nîmes as well as a second site at the public hospital in Alès. Oncogard’s medical team has continuously improved the quality of patient care through investment in modern radiotherapy equipment and the application of a multidisciplinary approach, supporting the provision of innovative and personalised treatments.
“The partnership with Stingray strengthens the future development of our centre in a model that allows us doctors to remain involved in the strategic decisions over the long term” says Eric Legouffe, shareholding doctor and managing director at Oncogard.
The Stingray team is particularly enthusiastic about partnering with a “medical team that has been recognised for years for its excellent reputation in the Gard, and beyond” as Ralph Hefti, CEO of Stingray, remarks.
The partnership with Oncogard, by way of a majority stake acquisition, expands Stingray’s presence in France, where the Group has been active for three years, concluding similar partnerships with leading physicians in Perpignan and Dunkirk.
Stingray has the ambition to become the independent European leader in radiotherapy and is therefore continuously looking for new partnerships with leading medical teams, particularly in France and Germany.